Johnson & Johnson Medical - OneTouch®Verio®IQ Blood Glucose Monitoring System

Therapeutic Goods Act 1989

Approval under section 42DF for use of restricted representations by Johnson & Johnson Medical Pty Ltd

I, Mick O'Connor, Director, Advertising Compliance Unit, Regulatory Practice, Education and Compliance Branch and Delegate of the Secretary to the Department of Health, on receipt of an application from InspireHCP Pty Ltd on behalf of Johnson & Johnson Medical Pty Ltd, have approved under section 42DF of the Therapeutic Goods Act 1989 (the Act) the restricted representations described in paragraph (a) below for use in advertisements directed to consumers, for the product identified in paragraph (b):

1. Representations which refer to 'diabetes', used in advertisements published in issues of 'That's Life!' magazine, available for sale in November 2015, December 2015 and/or January 2016, in the following contexts:
   • In the provision to consumers of accurate, balanced and not misleading contemporary information about diabetes generally; and
   • In the provision to consumers of accurate, balanced and not misleading contemporary information about the importance of monitoring blood glucose levels for people diagnosed with diabetes.
2. OneTouch®Verio®IQ Blood Glucose Monitoring System (ARTG No. 200176).

Dated this 26th day of October 2015

Signed electronically

Mick O'Connor
Delegate of the Secretary to the Department of Health; and
Director
Advertising Compliance Unit
Regulatory Practice, Education and Compliance Branch